The Losartan Intervention for Endpoint reduction in hypertension (LIFE) study demonstrated the clinical benefit of losartan-based therapy in hypertensive patients with left ventricular hypertrophy (LVH), mainly due to a highly significant 25% reduction in the relative risk of stroke compared with an atenolol-based regimen, for a similar reduction in blood pressure. The aim of this economic evaluation was to estimate the cost-effectiveness of losartan compared with atenolol from a UK national health system perspective. Quality-adjusted survival and direct medical costs were modelled beyond the trial using the within-trial incidence of stroke. Survival with stroke, study medication use and quality of life by stroke status were taken directly from the LIFE trial. The LIFE data were supplemented with UK data on lifetime direct medical costs of stroke and life expectancy in individuals without stroke. No additional stroke events or use of study treatment were assumed beyond the trial. Costs and benefits were discounted using current UK Treasury rates. In the base-case analysis, the reduction in stroke-related costs (by £968) offset 86% of the increase in study medication costs (£1128) among losartan-treated patients. The incremental cost-effectiveness ratio (ICER) for losartan versus atenolol in hypertensive patients with LVH was £2130 per qualityadjusted life year (QALY) gained ($3195/QALY), and this increased to £11 352 per QALY gained ($16 450/QALY) when the costs of stroke beyond the first 5 years were excluded. Thus, the clinical benefit of losartan was achieved at a cost well within reported thresholds for cost-effectiveness.
Introduction
Stroke is a major cause of death and long-term disability, and imposes a significant burden on society and healthcare systems. 1, 2 Patients with hypertension and left ventricular hypertrophy (LVH) are at particularly high risk of stroke. 3 The Losartan Intervention for Endpoint reduction in hypertension (LIFE) study 4 demonstrated the clinical benefit of losartan-based therapy over atenololbased therapy in hypertensive patients with electrocardiographic (ECG) evidence of LVH. The losartanbased regimen significantly reduced the adjusted combined risk of cardiovascular mortality and morbidity by 13% compared with the atenolol-based regimen, despite a similar degree of blood pressure control in each treatment group, suggesting that losartan has benefits beyond blood pressure reduction. The most clinically important finding in the LIFE study was the significant reduction in the incidence of stroke (risk reduction (RR) 25%) compared with a beta-blocker-based regimen, previously shown to reduce the incidence of stroke by 25-47% in placebo-controlled studies.
Stroke has very high direct and indirect costs both for the patient and family as well as for the health service. 8 However, although the costs associated with acute care have been widely reported, [9] [10] [11] relatively few studies have evaluated the long-term costs of stroke management. [12] [13] [14] [15] [16] [17] As stroke is a disease of the elderly, with an increasingly ageing population 18 it is anticipated that the incidence of stroke and associated demands on healthcare costs will rise substantially in the future. However, as healthcare funds are limited, cost-effective stroke prevention strategies are clearly needed. The LIFE study demonstrated the clinical benefit of losartanbased therapy in reducing the risk of stroke in hypertensive patients with LVH compared with an atenolol-based regimen, currently the most commonly prescribed antihypertensive therapy in the UK (as supported by IMS Market Trend Analysis (MTA) for UK Retail and Hospital, 19 based on days of therapy). The aim of this analysis was to evaluate the costs, benefits and cost-effectiveness of routine use of losartan compared with atenolol to prevent stroke in patients with hypertension and LVH, from the perspective of the UK National Health Service (NHS).
Methods

Clinical data
The LIFE study design, patient selection criteria and end point definitions have been described previously. 4 Briefly, LIFE was a double-blind, randomized, parallel-group study in 9193 patients (age range 55-80 years, 54% women) with essential hypertension (sitting blood pressure 160-200/95-115 mmHg) and ECG evidence of LVH. Patients were excluded from the study if they had secondary hypertension, myocardial infarction or stroke in the previous 6 months; angina pectoris requiring treatment with a beta-blocker or calcium antagonist; heart failure or LV ejection fraction p40%; or any disorder requiring treatment with an angiotensin II antagonist (AIIA), beta-blocker, angiotensin-converting enzyme inhibitor or hydrochlorothiazide.
After a 1-2 week placebo run-in period, patients were randomized to treatment with 50 mg losartan or 50 mg atenolol. Therapy was titrated to achieve a target blood pressure of p140/90 mmHg, by the addition of 12.5 mg hydrochlorothiazide after 2 months, doubling of the study therapy after 4 months and addition of open-label antihypertensive therapy if warranted after 6 months. The distribution of additional antihypertensive drugs on top of blinded study medication did not differ between the two groups.
Patients were enrolled from June 1995 to May 1997 by centres in the Nordic countries, the UK and the USA. After a mean follow-up of 4.8 years, treatment with losartan-based therapy significantly reduced the incidence of the primary composite end point (cardiovascular death, myocardial infarction or stroke) by 13%, compared with atenolol-based therapy. This treatment difference was primarily driven by the highly significant reduction (by 25%) in the incidence of fatal and non fatal stroke. There were no statistically significant differences between treatment groups in myocardial infarction or cardiovascular mortality as single end points. There was a significantly lower incidence of discontinuation due to adverse events with losartan-based therapy compared with atenolol-based therapy. 4 
Economic model
The LIFE economic evaluation combined aspects of both a within-trial economic evaluation and a lifetime projection of the difference in stroke incidence between losartan-based and atenololbased treatment regimens observed in the LIFE study. The impact of losartan-versus atenolol-based therapy on stroke RR and study medication use was confined to the within trial period (5.5 years). Thus, it was assumed that there was no additional stroke RR with losartan-based therapy beyond the trial period, and that patients stopped study treatment after 5.5 years or at the time of stroke, whichever occurred first.
Survival and the lifetime direct medical costs of managing stroke beyond the trial period were projected to incorporate the long-term effects of stroke on survival, quality-adjusted survival and resource use. This approach was similar to that adopted in the West of Scotland Coronary Prevention Study Group (WOSCOPS) economic evaluation. 20 Stopping the survival benefit at the end of the trial would not reflect the increased mortality associated with surviving a first stroke.
Survival was projected according to the patients' stroke status. Survival with stroke was determined from the LIFE database. Survival without stroke was determined from UK life tables, age and gender matched to the LIFE population. 21 
Resource use
Resource use included the costs of study medication as well as stroke-related costs.
Study medication. Medication use was based on losartan and atenolol use as recorded in the LIFE study. Only the costs of the intervention drug (losartan and atenolol) were included in the analysis since the distribution of hydrochlorothiazide and additional drugs on top of masked study drug did not significantly differ between the treatment groups. 4 To account for censoring, mean days on each dose level of losartan and atenolol were estimated using the two-stage method, 22 with local regressions to estimate the relationships between cumulative number of days on each dose level and survival. 23 The cost of study medication was based on the mean time on each dose of study medication (based on the LIFE data) and the current prices for losartan 50 and 100 mg and atenolol 50 and 100 mg in the UK.
Stroke-related costs. The base-case analysis used an estimate of the lifetime direct medical costs of managing stroke based on the Stroke Treatment Economic Model (STEM) to assess the cost-effectiveness of losartan in the prevention of stroke in patients with LVH.
14 Three secondary analyses were also conducted, each using different cost estimates.
In the base-case analysis, the direct costs of managing stroke were projected beyond the trial to the patient's lifetime, since the majority of direct costs of stroke are incurred beyond the acute management phase. The lifetime direct medical costs of managing stroke were based on the STEM estimate of d48 345 (1996 costs), 14 consistent with lifetime direct medical costs for stroke reported for other European countries, such as $73 333 in Sweden (1991 costs) 16 and $41 284 in the Netherlands (1991 costs). 17 For the purpose of this analysis, costs were inflated from 1996 (d48 345 (h70 100)) to 2003 values (d60 431 (h87 625)) using the consumer price index for health. 24 UK costs were assigned to all resources used to manage stroke in the STEM model.
Other analyses used cost estimates for the first 5 years after stroke including and excluding the cost of informal care, based on data from a large, randomized prospective study comparing different strategies for stroke care in the UK. 12 A Markov model was used to extrapolate costs over 5 years, and on this basis it was estimated that for every patient who experienced a stroke the cost to the NHS in the UK was d15 306 (h22 194) over 5 years. When informal care costs were included the stroke cost to the NHS increased to d29 405 (h42 637). This is a conservative estimate of informal care cost, since the minimum wage was used to value the time of the informal carer.
Clinical outcomes
The clinical outcomes estimated were the cumulative incidence of stroke, life years saved and qualityadjusted life years (QALYs) saved.
The within-trial (5.5 years) cumulative incidence of stroke was multiplied by the lifetime cost attributable to stroke to estimate lifetime stroke costs per patient per treatment group. The cumulative incidence of stroke after 5.5 years of patient follow-up was estimated using the cumulative incidence competing risks method to account for the possibility of death without prior stroke in patients classified as not having a stroke. 25 For consistency with the LIFE study clinical evaluation, we included adjustment for baseline degree of LVH and Framingham risk score.
Life years saved for losartan were estimated by multiplying the absolute RR in stroke by the additional life years expected by preventing a stroke. Life years gained by preventing a stroke were estimated by taking the difference between life expectancy for patients with and without a stroke. Life expectancy without stroke was estimated from UK life tables, 21 sex and gender matched to the LIFE population. Life expectancy with stroke was estimated with a Weibull model applied to the LIFE data with baseline degree of LVH, Framingham risk score, gender and age as covariates. The 95% confidence intervals (CI) and acceptance probabilities were based on a log-normal stroke cost distribution and the non-parametric bootstrap. 26 QALYs were estimated by weighting life years by health-related quality of life (QoL) as measured by a visual analogue scale in the LIFE study, at the randomization visit (prior to administration of the first dose) and every 6 months thereafter. After adjustment for baseline degree of LVH, baseline Framingham risk score, baseline QoL and month of follow-up using a repeated measures model, mean QoL was 71.4 for stroke-free patient months and 63.8 for patient months with stroke. First stroke was therefore associated with a decline of 7.6 points in QoL (95% CI: 6.6-8.7, Po0.0001). QALYs saved by preventing a stroke were estimated by taking the difference between the QALYs expected for patients not experiencing stroke and the QALYs expected for patients experiencing stroke. Thus, differences in QALYs were solely determined by differences in the incidence of stroke, and its consequences in terms of expected QALYs.
Discounting of costs and benefits
Costs were analysed using UK 2003 prices and discounted to present values at a rate corresponding to that recommended by the UK Treasury, at January 2005, 3.5%. 27 The stream of direct lifetime costs of stroke over the 15-year period from the STEM model was unavailable, and it was therefore not possible to calculate the net present value of stroke costs based on a 3.5% discount rate. Thus, the values reported in the STEM model based on the 6% discount rate were used. However, this assumption is conservative since a discount rate of 6% results in a lower estimate of lifetime cost of stroke than a discount rate of 3.5%. Health benefits were discounted at 3.5% per year.
Sensitivity analyses were conducted using basecase and other cost estimates. A further sensitivity analysis evaluated the effects of patients continuing to take losartan for their lifetime. Bootstrap analysis was used to estimate the probability of reaching different cost-effectiveness thresholds over a large number of replicates.
Results
Base-case analysis The costs and cumulative incidence of stroke during the LIFE trial period are summarized in Table 1 .
Although study medication costs per patient were higher for those randomized to losartan compared with those randomized to atenolol (by d1128 (h1636)), the reduction in stroke-related costs with losartan, due to the lower cumulative incidence of stroke with losartan (4.9% versus 6.5% with atenolol), offset most (86%) of the increase in medication cost.
Life years saved and QALYs saved by stroke reduction and incremental cost-effectiveness are summarized in Table 2 . As patients without stroke had a discounted (3.5%) life expectancy of 12.8 years, whereas patients with stroke had a discounted life expectancy of 8.4 years, prevention of stroke resulted in a gain of 4.4 years. The life years saved by losartan due to stroke reduction was 0.070. Thus, the incremental cost per life year saved was d1643 (h2380). Similarly, as patients without stroke would have a discounted quality adjusted life expectancy of 9.1 years, whereas patients with stroke had a discounted quality adjusted life expectancy of 5.7 years, prevention of stroke resulted in a gain of 3.4 QALYs. The QALYs saved by losartan due to stroke reduction was 0.054. Thus, the incremental cost per QALY saved for losartan was d2130 (h3195) ( Table 2) . Figures 1 and 2 show the probability of acceptability of losartan compared with atenolol for costeffectiveness thresholds up to d30 000 per life year saved and per QALYs saved, respectively. In each figure, the probabilities were calculated based on the proportion of bootstrap replicates that fell below the given cost-effectiveness threshold. For example, if the cost-effectiveness threshold was d25 000 per QALY saved, the probability that the cost per QALY ratio would exceed this threshold was approximately 5% (Figure 2 ). In both Figures 1 and 2 , the probability of acceptance crosses the y-axis at 0.40, indicating that losartan has a 40% chance of being cost saving.
Sensitivity analyses
Sensitivity analyses showed that the base-case costeffectiveness ratios were robust to variations in the cost of stroke (see Table 3 ). The incremental costeffectiveness ratio (ICER) of using losartan compared with atenolol in hypertensive patients with 
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LVH increased to d11 352 (h16 460) per QALY saved when stroke costs were estimated at d29 405 (h42 637) over 5 years. Under the very conservative assumption that stroke costs were d10 000 (h14 500) over 2 years, the ICER increased to d17 111 (h24 811). Adjusting the discount rate of costs to 6% reduced the ICER to d1185 per QALY saved. The probabilities of achieving particular costeffectiveness thresholds were reduced most markedly when the most conservative estimate of stroke costs (d10 000 (h14 500) over 2 years) was used (see Figures 3 and 4) . Assuming that patients continued to take losartan throughout their lifetime, the incremental cost per life year gained was d13 200 (95% CI: d2475-d34 785 (h19 140 (95% CI: h3589-[h50 438])) and the incremental cost per QALY was d17 111 (95% CI: d4580-d46 809) (h24 811 (95% CI: h6641-h67 872)). Table 3 Net costs, life years saved, quality-adjusted life years (QALYs) saved and incremental cost-effectiveness ratios (ICER, d) with 95% CIs Base case 5-year formal £15 306 stroke cost 2-year £10 000 stroke cost 5-year £29 405 stroke cost 6% discounting of costs probability of acceptance Base case 5-year formal £15 306 stroke cost 2-year £10 000 stroke cost 5-year £ 29 405 stroke cost 6% discounting of costs probability of acceptance Figure 4 Probability of acceptance for the base-case and sensitivity analyses for different cost-effectiveness thresholds (incremental cost per QALY saved).
Discussion
The 25% reduction in the incidence of stroke compared with treatment based on atenolol in the LIFE study clearly demonstrated the clinical benefit of losartan-based therapy in hypertensive patients with LVH. 4 This effect was seen over and above the benefits of blood pressure lowering. The present economic evaluation from a UK NHS perspective, consistent with a recent economic evaluation taken from the perspective of the Swedish health service, 28 demonstrates that the clinical benefit of losartan in terms of stroke reduction was achieved at a cost well within the range considered cost-effective in other studies. [29] [30] [31] [32] There are no defined limits for cost-effectiveness thresholds implemented by regulatory authorities. In the UK, retrospective analysis of previous resource allocation decisions made by the National Institute for Clinical Excellence indicated a threshold range of d20 000-d30 000 (h29 000-h43 500), below which an intervention may be considered cost-effective compared with the current standard of treatment. 33 This is consistent with data from a recent review of cost-effectiveness analysis in healthcare resource decision-making, 34 in which a cost-effectiveness threshold of $65 000 (h70 700) per life year gained (data inflated to 2002 exchange rates), was identified. 35 These inferred thresholds further emphasize that the clinical benefit associated with losartan therapy for stroke prevention is indeed cost-effective.
The results of this LIFE economic evaluation remained robust to varying assumptions regarding the unit cost of stroke. Losartan remained costeffective under the very conservative assumption of d10 000 stroke costs over 2 years, with the incremental cost per life year gained estimated at d13 200 and the incremental cost per QALY at d17 111.
Clearly, there are some limitations to this economic evaluation. Firstly, there are no available survival statistics for a cohort exactly matching the LIFE population to use as an estimate of the life expectancy for patients without stroke. In addition, while there was a statistically nonsignificant withintrial survival benefit overall for losartan, the mortality observed during the LIFE trial for patients not experiencing stroke (7.7%) was insufficient to obtain a reasonable estimate of life expectancy based on the trial data. Therefore, our approach was to obtain an estimate based on UK life-table statistics, age and gender matched to the LIFE population.
Secondly, the results of this economic evaluation were dependent on the STEM model, 14 which did not include specialist stroke units. In the UK, there has recently been a shift in clinical practice to the use of coordinated stroke services involving specialist stroke units, which are associated with improved treatment outcomes compared with more traditional treatment approaches, 36 at comparable cost. 37 The STEM model was based entirely on acute ischaemic stroke. In LIFE, 88% of the strokes were classified as ischaemic and the remainder haemorrhagic (10.2%) or other (1.8%). This most likely led to a more conservative (i.e. lower) estimate of the costs of stroke since the costs of treating haemorrhagic stroke, particularly subarachnoid haemorrhage, have been shown to be higher than those for ischaemic stroke. 38 Additionally, informal care and productivity costs were not incorporated into this analysis, and therefore the results provided are conservative when viewed from a societal perspective.
Finally, there is uncertainty about the life years saved and QALYs saved by losartan due to stroke RR. However, it is unlikely that the life years saved would be sufficiently low to raise the incremental cost per life year saved to d10 000 (h14 500). A threshold analysis indicates that the life years saved (or QALYs saved) would have to be 0.0115 years. This represents an 83% (79%) reduction from the base-case estimate and is smaller than the lower bound of the 95% CIs for life years saved of 0.026 (0.021 QALYs).
Western Europe, including the UK, has been described as a high-hypertension-prevalence, highstroke region. 39 The prevalence of hypertension in six European Union (EU) countries (including England) was estimated to be about 60% higher than in the USA and Canada. Recently, the impact of the use of losartan in the EU countries, projecting the reduction in stroke observed with losartan-based therapy in the LIFE study to each country, was reported. 40 For the UK, it was estimated that over one million individuals aged 55-80 years have hypertension in association with ECG-diagnosed LVH. The use of losartan-based therapy in preference to atenolol-based therapy in this population would be projected to prevent over 17 000 strokes over a 5.5-year period in the UK. Thus, widespread adoption of losartan (50-100 mg/day) for routine use in patients with hypertension and LVH would potentially have a major impact on public health in the UK. 40 Additionally, this clinical benefit would be cost-effective in accordance with reported costeffective thresholds. [29] [30] [31] [32] The efficacy of any therapeutic agent is dependent on correct dosing and titration. In the LIFE study, patients were titrated to achieve a target blood pressure of p140/90 mmHg, which is in accordance with current treatment recommendations. Clearly, it is important that such recommendations are implemented appropriately to optimize the clinical benefit of losartan.
It is possible that the magnitude of clinical benefit with losartan in the LIFE study is attributable to a class effect of the AIIAs. However, in the absence of data for other agents in this class, it would not be safe to assume equivalent clinical benefit and costeffectiveness to losartan. Data from studies with other AIIAs are required before assuming that the results observed in the LIFE study and reported here are due to a class effect of the AIIAs, as reflected in a recent report. 41 In conclusion, this economic evaluation has demonstrated that the clinical benefit of losartan compared with atenolol, as demonstrated in the LIFE study, was achieved at a cost well within reported thresholds for cost-effectiveness. Thus, losartan-based therapy (50-100 mg/day) is costeffective for the prevention of stroke in patients with hypertension and LVH and should be accepted in preference to atenolol-based therapy for routine use in the UK.
